About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Investor Centre
- Investor Centre
- News & ASX Announcements
Contact

Hit enter to search or ESC to close

Change of Company Name and ASX Code

May 24, 2019August 28, 2019

Click here to read more

Post navigation

2019 Annual General Meeting Results

Ashland Purchases Manufacturing Rights for VitalET and TPM

Related Posts

Phosphagenics’ PHN Trial Completes Enrolment and Dosing

December 17, 2015

Updated Non-Confidential Presentation CEO USA Roadshow

August 13, 2018

Phosphagenics Expands License Agreement for Diclofenac Gel

May 18, 2016

Recent Posts

Ashland Purchases Manufacturing Rights for VitalET and TPM
June 20, 2019
Change of Company Name and ASX Code
May 24, 2019
2019 Annual General Meeting Results
May 22, 2019

Categories

Analyst Coverage
Company Announcement
Company Report
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- News & ASX Announcements

© Copyright 2019 Avecho Biotechnology Ltd.